share_log

Mangoceuticals | 10-Q: Quarterly report

Mangoceuticals | 10-Q: Quarterly report

Mangoceuticals | 10-Q:季度報表
美股SEC公告 ·  11/15 05:25

牛牛AI助理已提取核心訊息

Mangoceuticals, Inc. reported financial results for the quarter ended September 30, 2024. Revenue for the quarter was $133,368, a decrease from $245,160 in the same period the previous year. Operating expenses totaled $1,840,745, slightly down from $1,944,049 in the prior year's quarter. The company experienced a net loss of $1,999,694, compared to a net loss of $1,799,460 in the same quarter of the previous year. The decrease in revenue and net loss was attributed to delays in marketing activities due to the migration to a new telehealth platform. For the nine months ended September 30, 2024, the company had a net loss of $6,758,630, with revenues of $510,626, an increase from $487,119 in the same period last year. The company's cash and cash equivalents stood at $73,912, down from $739,006 at the end...Show More
Mangoceuticals, Inc. reported financial results for the quarter ended September 30, 2024. Revenue for the quarter was $133,368, a decrease from $245,160 in the same period the previous year. Operating expenses totaled $1,840,745, slightly down from $1,944,049 in the prior year's quarter. The company experienced a net loss of $1,999,694, compared to a net loss of $1,799,460 in the same quarter of the previous year. The decrease in revenue and net loss was attributed to delays in marketing activities due to the migration to a new telehealth platform. For the nine months ended September 30, 2024, the company had a net loss of $6,758,630, with revenues of $510,626, an increase from $487,119 in the same period last year. The company's cash and cash equivalents stood at $73,912, down from $739,006 at the end of the previous year. Mangoceuticals also reported a working deficit of $1.3 million and an accumulated deficit of $17,985,966 as of September 30, 2024. The company highlighted the need for additional funding to support operations over the next 12 months and may seek additional funding through equity or debt financings. Mangoceuticals also mentioned a strategic review process to evaluate potential transactions that could result in a change of control or a significant change in operations.
Mangoceuticals公司報告了截至2024年9月30日的季度財務業績。本季度的營業收入爲133,368美元,較去年同期的245,160美元有所下降。營業費用總計爲1,840,745美元,較去年同期的1,944,049美元略有減少。與去年同期相比,公司經歷了1,999,694美元的淨虧損,而去年同期的淨虧損爲1,799,460美元。營業收入和淨虧損的減少歸因於由於遷移到一個新的遠程醫療平台導致的市場活動延遲。截至2024年9月30日的九個月,公司淨虧損爲6,758,630美元,營業收入爲510,626美元,較去年同期的487,119美元有所增加。公司的現金及現金等價物爲73,912美元,...展開全部
Mangoceuticals公司報告了截至2024年9月30日的季度財務業績。本季度的營業收入爲133,368美元,較去年同期的245,160美元有所下降。營業費用總計爲1,840,745美元,較去年同期的1,944,049美元略有減少。與去年同期相比,公司經歷了1,999,694美元的淨虧損,而去年同期的淨虧損爲1,799,460美元。營業收入和淨虧損的減少歸因於由於遷移到一個新的遠程醫療平台導致的市場活動延遲。截至2024年9月30日的九個月,公司淨虧損爲6,758,630美元,營業收入爲510,626美元,較去年同期的487,119美元有所增加。公司的現金及現金等價物爲73,912美元,較去年底的739,006美元有所下降。Mangoceuticals還報告了130萬美元的營運赤字和截至2024年9月30日的17,985,966美元的累積赤字。公司強調了在未來12個月內支持運營所需的額外資金,並可能通過股權或債務融資尋求額外資金。Mangoceuticals還提到了一項戰略審查流程,以評估可能導致控制權變更或運營發生重大變化的潛在交易。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。